A randomized trial comparing safety and efficacy of OKT3 and a monoclonal anti-interleukin-2 receptor antibody (BT563) in the prevention of acute rejection after heart transplantation

Transplantation

Volumn 62, Issue 1, 1996, Pages 51-55

  Van Gelder, Teun ^a   Balk, Aggie H M M ^a   Jonkman, Fokke A M ^a   Zietse, Robert ^a   Zondervan, Pieter ^a   Hesse, Cees J ^a   Vaessen, Lennart M B ^a   Mochtar, Bas ^a   Weimar, Willem ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INOLIMOMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; OKT 3;

ADULT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ELECTROSTIMULATION; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE ACTIVATION; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; COMMUNICABLE DISEASES; CYTOKINES; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; MALE; MIDDLE AGED; MUROMONAB-CD3; RECEPTORS, INTERLEUKIN-2;

EID: 0029887271     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199607150-00011     Document Type: Article

References (27)

1. Caillat-Zucman S, Blumenfeld N, Legendre C, et al. The OKT3 immunosuppressive effect. In situ antigenic modulation of human graft-infiltrating T cells. Transplantation 1990; 49: 156.
2. Norman DJ, Kahana L, Stuart FP Jr, et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993; 55: 44.
3. Balk AHMM, Simoons ML, Jutte NHPM, et al. Sequential OKT3 and cyclosporine after heart transplantation: a randomized study with single and cyclic OKT3. Clin Transplant 1991; 5: 301.
4. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313: 337.
5. Raasveld MHM, Hack CE, Ten Berge IJM. Activation of coagulation and fibrinolysis following OKT3 administration to renal transplant recipients: association with distinct mediators. Thromb Haemost 1992; 68: 264.
6. Grossi P, DeMaria R, Caroli A, et al. Infections in heart transplant recipients: the experience of the Italian heart transplant program. J Heart Lung Transplant 1992; 11: 847.
7. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990; 323: 1723.
8. Waldmann TA, Pastan IH, Gansow OA, et al. The multichain interleukin-2 receptor: a target for immunotherapy. Ann Int Med 1992; 116: 148.
9. Kirkman RL, Barrett LV, Gaulton GN, et al. The effect of anti-interleukin-2 receptor monoclonal antibody on allograft rejection. Transplantation 1985; 40: 719.
10. Kupiec-Weglinski JW, Diamantstein T, Tilney NL, et al. Therapy with monoclonal antibody to interleukin-2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats. Proc Natl Acad Sci USA 1986; 83: 2624.
11. Soulillou JP, Cantarovich D, LeMauff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antilymphocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322: 1175.
12. Hourmant M, Le Mauff B, Cantarovich D, et al. Prevention of acute rejection episodes with an anti-interleukin 2 receptor monoclonal antibody. Transplantation 1994; 57: 204.
13. Kirkman RL, Shapiro ME, Carpenter CB, et al. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation 1991; 51: 107.
14. Cantarovich D, Le Mauff B, Hourmant M, et al. Prevention of acute rejection episodes with an anti-interleukin 2 receptor monoclonal antibody. Transplantation 1994; 57: 198.
15. Neuhaus P, Keck H, Bechstein WO, et al. Quadruple induction immunosuppression after liver transplantation with IL-2 receptor antibody (BT563) is equally effective and better tolerated than ATG induction therapy. Transplant Proc 1993; 25: 587.
16. Friend PJ, Waldmann H, Cobbold S, et al. The anti-IL-2 receptor monoclonal antibody YTH-906 in liver transplantation. Transplantation 1991; 23: 1390.
17. Chatenoud L, Baudrihaye MF, Chkoff N, et al. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol 1986; 137: 830.
18. Van Gelder T, Daane CR, Vaessen LMB, et al. In vitro and in vivo effects of BT563, an anti-interleukin-2 receptor monoclonal antibody. Transpl Int 1994; 7 (suppl); S556.
19. International Society for Heart Transplantation. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J Heart Transplant 1990; 9: 587.
20. Kornfeld DS, Heller SS, Frank KA, Edie RN, Barsa J. Delirium after coronary artery bypass surgery. J Thorac Cardiovasc Surg 1978; 76: 93.
21. Van Gelder T, Mulder AH, Balk AHMM, et al. Intragraft monitoring of rejection following prophylactic treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in heart transplant recipients. J Heart Lung Transplant 1995; 14: 346.
22. Balk AHMM, Weimar W, Rothbarth PH, et al. Passive immunization against cytomegalovirus in allograft recipients. The Rotterdam Heart Transplant Program experience. Infection 1993; 21: 1.
23. Brouwer RML, Balk AHMM, Weimar W. OKT3 and the incidence of lymphoproliferative disorders after cardiac transplantation. N Engl J Med 1991; 324: 1437.
24. Zipes DP. Management of cardiac arrhythmias: pharmacological, electrical and surgical techniques. In: Braunwald, ed. Heart disease, a textbook of cardiovascular medicine, 4th ed. Philadelphia: Saunders, 1992.
25. Van Gelder T, Zietse R, Mulder AH, et al. A double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration in the prevention of acute rejection after kidney transplantation. Transplantation 1995; 60: 248.
26. Tellides G, Dallman MJ, Morris PJ. Synergistic interaction of cyclosporine A with interleukin 2 receptor monoclonal antibody therapy. Transplant Proc 1988; 20: 202.
27. Kupiec-Weglinski JW, Hahn HJ, Kirkman RL, et al. Cyclosporine potentiates the immunosuppressive effects of anti-interleukin 2 receptor monoclonal antibody therapy. Transplant Proc 1988; 20: 207.